Floridienne (FLOB) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
30 Sep, 2026Executive summary
Turnover increased to EUR 348.3 million as at 30 June 2026, up 3.2% year-over-year, with all divisions contributing to growth despite a challenging macroeconomic environment.
EBITDA rose 12.5% to EUR 40.5 million, driven by higher sales, cost control, and efficient production.
Net result improved significantly to EUR 1.3 million from a loss of EUR 8.2 million in H1 2025.
All divisions reported improved profitability, with notable recovery in the Recycling Division and record performance in BIOTROP.
Positive outlook for the full year, with confidence in further improvement over 2025.
Financial highlights
Consolidated turnover: EUR 348.3 million (+3.2% year-over-year).
EBITDA: EUR 40.5 million (+12.5% year-over-year).
Net result: EUR 1.3 million (vs. -EUR 8.2 million in H1 2025).
Equity capital: EUR 677.8 million, up EUR 58.9 million since December 2025.
Net financial debt: EUR 302.7 million, up from EUR 266.5 million at year-end 2025.
Outlook and guidance
Board expects better results for 2026 compared to 2025, supported by strong H1 performance.
Life Sciences Division anticipates continued growth, especially with BIOTROP's expansion in Europe and North America.
Food Division expects profitability improvements to persist, especially during the holiday season.
Recycling Division to benefit from new installations and regulatory tailwinds.
External risks monitored include Middle East conflict, energy costs, interest rates, and potential El Niño impacts.
Latest events from Floridienne
- Strong Q1 2026 growth in sales and profitability across all divisions, with a positive outlook.FLOB
Q1 2026 TU - Strong turnover and EBITDA growth driven by Life Sciences and Biotrop integration; positive 2024 outlook.FLOB
H1 2024 - Sales up 25% and record EBITDA, led by Life Sciences and Food, offsetting Chemicals' decline.FLOB
Q3 2024 TU - Record EBITDA and net profit in 2024, led by Life Sciences and BIOTROP integration.FLOB
H2 2024 - Turnover up 6.3% year-over-year, but net result drops to EUR -8.2 million on currency volatility.FLOB
H1 2025 - Q1 2025 sales rose, led by Life Sciences, while Chemicals faced margin pressure from low metal prices.FLOB
Q1 2025 TU - BIOTROP's exceptional growth and strategic investments drive confidence in sustained expansion.FLOB
Q3 2025 TU - Turnover rose to EUR 725.9 million, but profitability fell due to currency and inflation impacts.FLOB
H2 2025